Keywords: somatic evolution, mutations in cancer, cancer type, amino acid substitutions, proteome composition.
Introduction
Cancer arises in somatic evolution in tissues when a cell acquires a sufficient number of "driver" mutations that promote its unrestrained proliferation, growth, dissemination and invasion. Yet, most mutations in the cancer cell are "passenger" mutations that accumulate during the cell's lifetime in a buildup of DNA damage. Latest advances in comprehensive sequencing, the genome-wide association study approach and the worldwide effort in creation of large public cancer databases have granted significant progress in studies of mutational landscape in cancer. Recent profound analyses of nucleotide alteration signatures attributed mutational profiles to effects of external and internal deleterious factors in different cancer types. 1, 2 Nonsynonymous substitutions in the nucleotide sequence of a protein-coding part of a gene ultimately result in changes of the amino acid composition of the protein product of the gene, and consequently in changes of the structure and properties of the protein. However, though mutations in individual cancer driver proteins are broadly studied, few studies only have examined the global landscape of amino acid substitutions in cancer. 3, 4 We have recently shown, that somatic evolution in cancer consistently changes composition of the cancer cell proteome, where some amino acids permanently disappear from, and others are de novo introduced into proteins across multiple cancer types. 4 We found, that Arg is by far the most prominent irreversible loss and His and Cys are the most substantial de novo gains in proteins in cancer, but other amino acids are also steadily lost or gained, thus making somatic evolution in cancer asymmetric. In the total cancer proteome, Ala, Asp, Glu, Gly, Pro and Ser universally disappear from the protein composition, while Phe, Ile, Lys, Leu, Met, Asn, Gln, Thr, Val, Trp, Tyr are almost constantly gained. However, the magnitudes of the amino acid gains/losses vary extensively between cancer types, thus creating distinctive molecular profiles of their somatic evolution.
In the present study, we analyzed profiles of mutation-induced alterations of the proteome composition in 23 human cancer types, using data on over three million amino acid substitutions in twenty-one thousand cancer samples from the Catalogue of Somatic Mutations in Cancer (COSMIC; v81) database. 5 We show that in a majority of the cancer types, their tissue-specific somatic evolution introduces characteristic changes into composition of proteins. We found that within-cancer similarities of amino acid gains and losses in samples vary between the cancer types, with the most homogeneous profiles in skin, cervical and endometrial cancers, and most heterogeneous profiles in kidney, ovarian and bone cancers. We demonstrate that the cancerspecific amino acid gain/loss signatures can be recognized with a machine learning algorithm in several cancer types.
Materials and Methods
We extracted information on nucleotide substitutions and resulting amino acid substitutions from the COSMIC (v81) database (http://cancer.sanger.ac.uk). The analysis of the data was performed in R version 3.3.1 6 using RStudio version 0.99.893.
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Results
From the COSMIC v81 database, 5 we extracted data on amino acid substitutions in proteins that arise from single nucleotide substitutions in the total of twenty-one thousand cancer samples.
Missense and nonsense single nucleotide substitutions make a majority of the data in the COSMIC database, comprising about 93% of entries. Of these, nonsynonymous substitutions are 75%. We analyzed data on over three million amino acid substitutions for 23 cancer types, for 4 which the number of tumor samples exceeds one hundred in the COSMIC database. 
Case studies of skin, cervical and endometrial cancers
We analyzed gains/losses of amino acids on the level of individual proteins in cancers of skin, endometrium and cervix. For each cancer type, we calculated numbers of proteins that undergo net gains/losses of its five most frequently gained and most frequently lost amino acids ( Figure   4 ). For instance, the protein coded by the UBR4 gene gains Phe residues thirty times more often 10 than it loses them in all skin cancer samples combined, and is therefore counted as having gained
Phe. In this way, we evaluate the scope of the proteome alterations in each of the three cancer types. In individual tumor samples, the numbers of proteins that undergo net changes of their amino acid composition depend on the severity of the tumor mutation load. Interestingly, the p53 protein gains Trp against the prevalent tendency of losing the amino acid in skin cancer (Table S1 ). In highly mutated skin tumors, the gains and losses can potentially affect The alterations are consistent with the most prevalent substitutions of Arg being those by Cys, His, Gln, Trp and truncations. 3, 4 The exceptionally high irreversible loss of Arg is associated 13 with the codons for the amino acid that contain the CG sequence in their composition. 4 The codons are most likely affected by spontaneous deamination of methylated cytosines in CpG sequences 9 that is observed in many cancer types of epithelial origin with high cell turnover. 10 All samples of endometrial cancer were used to calculate numbers of proteins that undergo gains/losses of its most frequently gained and frequently lost amino acids. The tumor suppressor proteins p53 (28.9% tumor samples contain at least one mutation in the gene coding for the protein) and FBXW7 (17.6% samples) demonstrate extraordinarily frequent losses of Arg with simultaneous gains of Cys residues. Loss of Arg is an important alteration in the p53 protein where the amino acid residues participate in interactions with DNA, and it thus has an exceptionally high ratio of events of irreversible loss of Arg to the number of Arg residues in its molecule in cancer mutations. 4 12 and frequent mutations that change C to T or C to G are associated with activity of APOBEC family of cytidine deaminases that are innate immunity enzymes attacking retroviruses. 13 Glu, Arg, Asp, Gly and Pro are five amino acid residues that are most frequently irreversibly lost in somatic evolution of cervical cancer. Lys, Asn, Gln, His and Cys are five most frequently gained amino acid residues. Similarly to endometrial cancer, the tumor suppressor protein FBXW7 (10% of samples are affected by at least one amino acid substitution in the protein) loses Arg and gains Cys, the PIK3CA protein (28.3% samples) loses Glu and gains Lys, and the KRAS protein (5.6% samples) loses Gly.
Correlation analyses and hierarchical clustering analyses within 23 cancer types
We performed correlation analyses and hierarchical clustering analyses of net amino acid gains/losses for each tissue. Supposedly, Pearson correlation coefficients r that are close to |1|
indicate that respective amino acids are constantly gained/lost together or either one of the amino acids is lost and the other is gained at equal rates in most samples in the cancer type.
Consistently high correlation coefficients of gains and losses of amino acids in a cancer type indicate presence of a uniform amino acid gain/loss signature caused by a same mutational (Table S2   16 summarizes correlation matrices for all the cancer types), while the cancer types with lowest correlation scores are those of autonomic ganglia, ovary, bone and central nervous system. 
Machine learning analysis
We divided data on each cancer type into quartiles based on the number of mutations in tumor samples. For the quartiles of most heavily mutated samples in each cancer type, we performed a machine learning (ML) analysis of gains/losses of amino acids using the K-nearest neighbor method. We found that the ML analysis could indeed distinguish among different cancer types from their amino acid gain/loss profiles, albeit with unequal sensitivity. Skin, large intestine and lung cancers were the most accurately classified tissue types ( Figure 7) , with as much as 95%
cases of skin cancer being correctly attributed. We suggest that the accuracy of the classification depends on the prominence and homogeneity of the cancer type-specific signature, number of analyzed tissue samples, and median number of mutations in the cancer type. For instance, skin cancer has a very distinct signature, uniformity of amino acid gains/losses throughout the samples, the highest median number of mutations of all cancer types, and a substantial though not the biggest number of samples in the database. Alhough amino acid gain/loss signatures of lung and large intestine cancers seem to be less divergent from those in other tissues than that of skin cancer (Figure 2 ), the cancer types are detected with 83% and 64% accuracy, respectively.
The both cancer types are represented with high numbers of samples in the database, mostly have many mutations per sample and high amino acid gain/loss correlation scores ( Figure 5 ).
However, cancers of the central nervous system and those of hematopoietic and lymphoid tissue are reasonably well detected with the ML (56% and 58% accuracy, respectively) despite low median numbers of mutations and low to medium correlation scores. Interestingly, only 23% cases of breast cancer were correctly attributed despite its having the second biggest number of cases in the database and moderately high amino acid gain/loss correlation score. Accuracy of detection of breast cancer is thus smaller than that of cervical cancer with a tenfold smaller number of samples. The finding may indicate heterogeneity of breast cancer types due to a bigger variety of underlying molecular processes compared to those of skin or lung cancers.
Remarkably, the ML model failed to detect soft tissue, biliary tract, bone and ovarian cancers. 
Associations of cancer types according to their amino acid gain/loss profiles
We analyzed associations of cancer types according to their amino acid gain/loss profiles ( Figure 8 ). We found, that prostate cancer clusters most closely with pancreatic cancer, followed by cancers of central nervous system and blood. Cancer of autonomic ganglia clusters very closely with that of adrenal gland. Similarly, stomach and large intestine cancers cluster together.
Unexpectedly, bone tissue cancer clusters tightly with that of biliary tract. The finding may be attributed to the small sample numbers of the cancer types in the database. The similarity of amino acid gain/loss profiles of cancers of cervix and urinary tract may be due to human papillomavirus being also active in urinary tract cancer 14 into stop codons, truncation events. We have shown that the net outcome of single nucleotide substitutions across multiple cancer types is a change of amino acid frequencies in the composition of proteins that makes the somatic evolution in cancer asymmetric and not in equilibrium. 4 Six amino acids (Ala, Asp, Gln, Gly, Ser, and Arg) are irreversibly lost and the rest of amino acids are gained in a majority of cancer types. Largely, the somatic evolution in cancer shows prominent similarities with evolution of the proteome that accompanies increasing complexity of organisms. 15 In the both processes, Pro, Ala, Gly and Glu are consistently lost, and
Cys, Met, His and Phe are strongly accrued. Strikingly, while Arg did not show a universal trend either to be gained or lost in phylogenetic evolution, 15 it is the most prominent irreversible loss in somatic evolution in cancer. We have shown that the unusual loss of Arg is associated with substitutions in the four codons out of the six coding for the amino acid that contain CG sequence in their composition. The extraordinary targeting of the CG sequence-containing codons for Arg is conceivably explained by spontaneous deamination of methylated cytosines in CpG sequences, 7 as the CG sequence-containing codons for Ala, Pro, Thr and Ser also demonstrate moderately elevated mutation rates. 4 DNA methylation is an epigenetic modification that increases with age 16 and is believed to play a role in cancer. 17 Presumably, loss of Arg is counteracted with a strong pressure of negative selection in phylogenetic evolution, while negative selection is largely absent for coding substitutions in cancer. 18 Conversely, as evolution of species proceeds through germ cells originating from young organisms, fewer methylation sites may be present in them, and therefore fewer deamination events. However, the preponderance of irreversible loss of Arg in cancer deserves further analysis. Additionally, there are a number of other differences between somatic evolution in cancer and phylogenetic evolution. While Ser is reported to be vigorously gained in phylogenetic evolution, it is mostly lost in mutagenesis in cancer, with several tissues demonstrating very high losses of the amino acid ( Figure 1 ). Furthermore, Lys is weakly lost in evolution of species, but predominantly gained in somatic evolution in cancer, mostly in the E>K substitution. Tyr and Trp accumulate in proteins in most cancer types, with few exceptions, but were not shown to accumulate consistently in evolution of species despite being evolutionary young amino acids. 15 While the general tendencies of the asymmetric gains and losses of amino acids are largely consistent across 23 human cancer types in our analysis, their scopes vary significantly due to differences in mutational processes among the cancer types. Each type of either DNA damage or deficient DNA repair or replicative component has its own predilection for specific nucleotides, which can produce recognizable patterns of mutagenesis. 1, 2, 19 The mutational signatures of a tumor may provide information on routes and mechanisms leading to cancer in each cancer type. 20 We show here that at least several specific patterns of nucleotide alterations produce distinct amino acid gain/loss profiles in some cancer types, where gains and losses of some but not other amino acids cause marked changes in the proteome composition ( Figure 3) . genes coding for DNA polymerases Pol δ and Pol ε in a few hypermutated tumor samples. The analysis suggests that the more complex assortment of mutational processes in some cancer types leads to weaker correlations of gains and losses of amino acids. The least amino acid gain/loss homogeneity was found in cancers of kidney, autonomic ganglia, ovary, bone or central nervous system. However, with mutation data on large numbers of samples it may be possible to cluster tumors within the cancer types according to their amino acid gain/loss profiles and potentially obtain information about underlying mutational processes. A machine learning algorithm using amino acid gain/loss signatures of the cancer types was able to attribute some cancer types more accurately than others, with skin cancer being the topmost correctly assigned. We suppose that a combination of the distinctivity of the amino acid gain/loss signature of a cancer type and/or its homogeneity in the available samples, the median number of mutations and the number of samples in the database influenced the ability of the algorithm to recognize cancer types.
While it takes a small number of driver mutations to cause and sustain cancer, the accompanying passenger mutations if present in high numbers may result in distinct changes of the composition of the proteome in different cancer types and therefore elevated metabolic demands for some of de novo gained amino acids. Furthermore, though not selected specifically for individual proteins or residue sites, some of changes may increase fitness of the cancer cell. 
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